Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six‐month, randomized, placebo‐controlled, double‐blind clinical trial

Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin‐induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in body weight. We measured, for the first time, lipid particle quantification, lipid peroxidation, appetite‐regulating hormones and mRNA expression of the 5‐hydroxytryptamine 2c receptor (5‐HT2c receptor). A total of 48 obese participants were enrolled in this six‐month, randomized (1:1), placebo‐controlled, double‐blinded clinical trial. Lorcaserin treatment reduced fat mass (P